Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

364 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022-2024: results from the CLEAR registry.
Zhanel GG, Dhami R, Baxter M, Wong M, Mirzanejad Y, Kosar J, Cervera C, Irfan N, Borgia S, Serebryanskyy A, Ariano R, Savoie M, Tascini C, Walkty A, Karlowsky JA. Zhanel GG, et al. Among authors: tascini c. Expert Rev Anti Infect Ther. 2024 Sep 26:1-8. doi: 10.1080/14787210.2024.2405930. Online ahead of print. Expert Rev Anti Infect Ther. 2024. PMID: 39324660
How is ceftobiprole used in Canada: the CLEAR study final results.
Zhanel GG, Kosar J, Baxter M, Dhami R, Borgia S, Irfan N, Dow G, Dube M, von den Baumen TR, Tascini C, Lee A, Chagla Z, Girouard G, Bourassa-Blanchette S, Wu M, Keynan Y, Walkty A, Karlowsky JA. Zhanel GG, et al. Among authors: tascini c. Expert Rev Anti Infect Ther. 2024 Aug;22(8):681-688. doi: 10.1080/14787210.2024.2374280. Epub 2024 Jul 15. Expert Rev Anti Infect Ther. 2024. PMID: 39008122
Cefepime-Taniborbactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Zhanel GG, Mansour C, Mikolayanko S, Lawrence CK, Zelenitsky S, Ramirez D, Schweizer F, Bay D, Adam H, Lagacé-Wiens P, Walkty A, Irfan N, Clark N, Nicolau D, Tascini C, Karlowsky JA. Zhanel GG, et al. Among authors: tascini c. Drugs. 2024 Oct;84(10):1219-1250. doi: 10.1007/s40265-024-02082-9. Epub 2024 Aug 30. Drugs. 2024. PMID: 39214942 Review.
COAGULATIVE BIOMARKERS DIFFERENTLY PREDICT CLINICAL OUTCOMES IN INVASIVE INFECTIONS CAUSED BY NEISSERIA MENINGITIDIS AND STREPTOCOCCUS PNEUMONIAE.
Meini S, Bracalente I, Sbrana F, Ripoli A, Andreini R, Galli R, Leonardi S, Attanasio V, Carannante N, Bernardo M, Viaggi B, Martini L, Giuliano S, Tascini C. Meini S, et al. Among authors: tascini c. Am J Med. 2024 Nov 12:S0002-9343(24)00701-0. doi: 10.1016/j.amjmed.2024.10.020. Online ahead of print. Am J Med. 2024. PMID: 39542076
Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.
Mazzotta V, Mazzaferri F, Lanini S, Mirandola M, Cozzi Lepri A, Vergori A, Savoldi A, Santoro A, Maccarrone G, Mastrorosa I, Simonetti O, Zottis F, Nicastri E, Rosini G, Rovigo L, Tavernaro L, Sarmati L, Tascini C, Girardi E, Cattelan AM, Antinori A, Tacconelli E; MANTICO2/MONET study group. Mazzotta V, et al. Among authors: tascini c. J Infect. 2024 Nov;89(5):106294. doi: 10.1016/j.jinf.2024.106294. Epub 2024 Sep 27. J Infect. 2024. PMID: 39343244 Free article. Clinical Trial.
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view.
Cingolani A, Tavelli A, De Benedittis S, Mastrorosa I, Muccini C, Bini T, Carraro A, Compagno M, Mazzitelli M, Guastavigna M, Cernuschi M, Torti C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study group. Cingolani A, et al. J Antimicrob Chemother. 2024 Oct 1;79(10):2662-2667. doi: 10.1093/jac/dkae273. J Antimicrob Chemother. 2024. PMID: 39140512
364 results